Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Amphetamine sulfate
Drug ID BADD_D00131
Description Amphetamine, a compound discovered over 100 years ago, is one of the more restricted controlled drugs. It was previously used for a large variety of conditions and this changed until this point where its use is highly restricted. Amphetamine, with the chemical formula alpha-methylphenethylamine, was discovered in 1910 and first synthesized by 1927. After being proven to reduce drug-induced anesthesia and produce arousal and insomnia, amphetamine racemic mix was registered by Smith, Kline and French in 1935. Amphetamine structure presents one chiral center and it exists in the form of dextro- and levo-isomers.[A18540] The first product of Smith, Kline and French was approved by the FDA on 1976.[L5194] During World War II, amphetamine was used to promote wakefulness in the soldiers. This use derived into a large overproduction of amphetamine and all the surplus after the war finalized ended up in the black market, producing the initiation of the illicit abuse.[A18540]
Indications and Usage Amphetamine is indicated for the treatment of attention-deficit/hyperactivity disorders (ADHD) as well as for the treatment of central nervous system disorders such as narcolepsy.[A18540] ADHD is a complex disorder associated with the substantial heterogeneity in etiology, clinical presentation, and treatment outcome. ADHD comes from a complex interplay between interdependent genetic and non-genetic factors which cause complex mental disorders in children and teenagers.[A174271] On the other hand, narcolepsy is a chronic sleep disorder typically resenting during adolescence and characterized by excessive daytime sleepiness.[A174274] Amphetamine is also being used nowadays off-label for the treatment of obesity, depression and chronic pain.[A174268, A174283]
Marketing Status approved; illicit; investigational
ATC Code N06BA01
DrugBank ID DB00182
KEGG ID D02074
MeSH ID D000661
PubChem ID 6055
TTD Drug ID D05BMG
NDC Product Code 59917-225; 24338-031; 52536-057; 52536-059; 63629-2078; 71337-024; 59917-226; 59917-228; 24338-026; 57664-062; 67877-711; 70010-040; 0406-1220; 63629-2079; 63629-1115; 70010-041; 0527-2524; 0527-2525; 49812-0059; 61960-0200; 24338-035; 43547-457; 63629-2499; 0406-1219; 71337-025; 72162-1088; 51634-0224; 59917-227; 65392-0110; 13107-260; 24338-037; 43547-458; 0406-4942; 13107-259; 24338-033; 57664-075; 63629-2498; 24338-022; 63629-1114; 67877-710; 0792-3936
UNII 6DPV8NK46S
Synonyms Amphetamine | Amfetamine | Phenopromin | Desoxynorephedrin | Phenamine | Centramina | Fenamine | Mydrial | Thyramine | Amphetamine Sulfate | Sulfate, Amphetamine | Amphetamine Sulfate (2:1) | l-Amphetamine | l Amphetamine | levo-Amphetamine | levo Amphetamine | Levoamphetamine
Chemical Information
Molecular Formula C18H28N2O4S
CAS Registry Number 60-13-9
SMILES CC(CC1=CC=CC=C1)N.CC(CC1=CC=CC=C1)N.OS(=O)(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood pressure increased13.14.03.005--Not Available
Constipation07.02.02.001--
Diarrhoea07.02.01.001--
Dizziness24.06.02.007; 17.02.05.003; 02.11.04.006--
Dry mouth07.06.01.002--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyskinesia17.01.02.006--
Dysphoria19.04.02.004--Not Available
Erection increased21.03.01.004; 19.08.04.002--Not Available
Euphoric mood19.04.02.006--
Headache17.14.01.001--
Insomnia19.02.01.002; 17.15.03.002--
Palpitations02.11.04.012--
Restlessness19.11.02.002; 17.02.05.021--
Rhabdomyolysis15.05.05.002--
Tachycardia02.03.02.007--Not Available
Tic19.11.04.001; 17.02.05.024--Not Available
Tourette's disorder19.11.04.002; 17.19.02.001; 03.10.01.001--Not Available
Tremor17.01.06.002--
Urticaria10.01.06.001; 23.04.02.001--
Weight decreased13.15.01.005--
Libido disorder21.03.02.006; 19.08.03.004--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Psychotic disorder19.03.01.002--
Device stimulation issue27.01.02.005--Not Available
The 1th Page    1    Total 1 Pages